ID 原文 译文
937 呼吸道标本采集、核酸检测和病毒培养等操作，个人防护应按照BSL-3级实验室防护要求。 Personal protection should be taken in accordance with BSL-3 laboratory protection requirements for Respiratory tract specimen collection, nucleic acid detection and virus culture operations.
938 血常规、生化、免疫检验等常规检验操作，个人防护应按照BSL-2级实验室防护要求。 Personal protection in accordance with BSL-2 laboratory protection requirement should be carried out for biochemical, immunological tests and other routine laboratory tests.
939 标本运送应采用符合生物安全要求的专用运输罐和运输箱。 Specimens should be transported in special transport tanks and boxes that meet biosafety requirements.
940 所有实验室废弃物均应严格高压消毒处理。 All laboratory waste should be strictly autoclaved.
941 三. COVID-19患者肺部影像学表现 III. Imaging Findings of COVID-19 Patients
942 肺部影像学检查在COVID-19诊断、疗效监测及出院评估中具有重要价值。 Thoracic imaging is of great value in the diagnosis of COVID-19, monitoring of therapeutic efficacy, and patient discharge assessment.
943 检查方法首选肺部高分辨率CT；对于不便搬动的危重型患者，可选择床旁X线检查。 A high-resolution CT is highly preferable. Portable chest X-rays are helpful for critically ill patients who are immobile.
944 一般于入院当日行基线肺部CT检查，若治疗后疗效不理想，2~3d后可复查肺部CT；治疗后症状稳定或好转，可5~7d后复查 CT for baseline evaluation of patients with COVID-19 is usually performed on the day of admission, or if ideal therapeutic efficacy is not reached, it can be re-performed after 2 to 3 days. If symptoms are stable or improved after treatment, the chest CT scan can be reviewed after 5 to 7 days.
945 危重型患者须每日复查床边胸片。 Daily routine portable chest X-rays are recommended for critically ill patients.
946 COVID-19患者肺部CT早期多表现为位于肺外带、胸膜下、下叶分布的多发性斑片状磨玻璃阴影，病灶长轴多与胸膜平行； COVID-19 at the early stage often presents with multifocal patchy shadows or ground glass opacities located in the lung periphery, subpleural area, and both lower lobes on chest CT scans. The long axis of the lesion is mostly parallel to the pleura.